IMCR: イムノコア・ホールディングス

IMCR News

• 16:50 Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
• 15:12 EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
• 14:10 AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study
• 12:58 TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
• 18:36 Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition
• 14:45 Reasons Why Investors Should Consider Betting on Neurocrine Stock
• 12:55 UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
• 18:13 NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population
• 14:42 Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
• 13:34 CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
• 13:32 PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
• 14:41 Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
• 14:41 VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
• 13:30 Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
• 13:22 SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study
• 09:06 AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
• 15:15 EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
• 17:02 MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
• 15:36 J&J Wins CHMP Nod for Expanded Use of Multiple Myeloma Drug Tecvayli
• 15:22 ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases
• 15:15 ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
• 13:52 AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
• 12:49 Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
• 14:43 IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati